[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

8 Major NSCLC Markets to Gain Rapid Traction to 2025, Expects GlobalData in Its Report Available at MarketPublishers.com

22 Feb 2017 • by Natalie Aster

LONDON –  The worldwide NSCLC market is expected to gain rapid traction over the next few years, driven by the surging use of premium-priced immune checkpoint inhibitors in the treatment of this disease, specifically in the initial phase. Immunotherapies are expected to reach USD 17.5 billion in sales in the in the NSCLC market by 2025-end, grabbing nearly 65% of total sales.

The market growth is also expected to be fuelled by the increasing incidence rates of NSCLC in 8MM, progressively with the ageing population. Overall, the incidence of NSCLC across the leading 8 markets is set to grow an AGR of 3.1% through to 2025. China is poised to witness the most remarkable growth, with its NSCLC incident cases surging at an AGR of 4.7%. Additionally, the expected increase in branded therapy prescriptions in China are expected to drive the market growth both in China and the rest of 8MM.

Patent expiration of a range of blockbuster drugs, such as Tarceva and Alimta, among others, and the introduction of generics are the factors restraining the market growth. Patented drug sales across the 8MM are poised to decrease to USD 18 million by 2025.

The global NSCLC therapeutics market value stood at USD 6.2 billion as of 2015, and it is expected to register a positive CAGR of 15.7%, amounting to USD 26.71 billion in the 8MM by 2025.

In-demand research report “PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025” prepared by GlobalData examines the market covering NSCLC-specific drug sales across the 8MM such as 5EU, the USA, China, and Japan.

The study includes historical and forecast market revenue data, yearly cost of therapy, and key product sales in 17 patient segments. It identifies the key unmet needs in the marketplace, outlines opportunities, reviews R&D strategies, describes the clinical trial landscape, and contains an extensive pipeline analysis. The research sheds light on the major industry drivers, limiters, and challenges. It canvasses the degree of competition in the global NSCLC market as of now and in the offing.

More in-demand market studies by our partner are available at its page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest